These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 36894938)
1. Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes. Ferdinand KC; Dunn J; Nicolay C; Sam F; Blue EK; Wang H Cardiovasc Diabetol; 2023 Mar; 22(1):49. PubMed ID: 36894938 [TBL] [Abstract][Full Text] [Related]
2. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Ferdinand KC; White WB; Calhoun DA; Lonn EM; Sager PT; Brunelle R; Jiang HH; Threlkeld RJ; Robertson KE; Geiger MJ Hypertension; 2014 Oct; 64(4):731-7. PubMed ID: 24980665 [TBL] [Abstract][Full Text] [Related]
3. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5). Skrivanek Z; Gaydos BL; Chien JY; Geiger MJ; Heathman MA; Berry S; Anderson JH; Forst T; Milicevic Z; Berry D Diabetes Obes Metab; 2014 Aug; 16(8):748-56. PubMed ID: 24762094 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757 [TBL] [Abstract][Full Text] [Related]
5. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9). Pozzilli P; Norwood P; Jódar E; Davies MJ; Ivanyi T; Jiang H; Woodward DB; Milicevic Z Diabetes Obes Metab; 2017 Jul; 19(7):1024-1031. PubMed ID: 28294499 [TBL] [Abstract][Full Text] [Related]
6. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8). Dungan KM; Weitgasser R; Perez Manghi F; Pintilei E; Fahrbach JL; Jiang HH; Shell J; Robertson KE Diabetes Obes Metab; 2016 May; 18(5):475-82. PubMed ID: 26799540 [TBL] [Abstract][Full Text] [Related]
7. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c. Gallwitz B; Dagogo-Jack S; Thieu V; Garcia-Perez LE; Pavo I; Yu M; Robertson KE; Zhang N; Giorgino F Diabetes Obes Metab; 2018 Feb; 20(2):409-418. PubMed ID: 28817231 [TBL] [Abstract][Full Text] [Related]
8. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Dungan KM; Povedano ST; Forst T; González JG; Atisso C; Sealls W; Fahrbach JL Lancet; 2014 Oct; 384(9951):1349-57. PubMed ID: 25018121 [TBL] [Abstract][Full Text] [Related]
9. Dulaglutide for the treatment of type 2 diabetes. Scheen AJ Expert Opin Biol Ther; 2017 Apr; 17(4):485-496. PubMed ID: 28274140 [TBL] [Abstract][Full Text] [Related]
10. EFFICACY AND SAFETY OF DULAGLUTIDE IN HISPANIC/LATINO PATIENTS WITH TYPE 2 DIABETES IN THE AWARD CLINICAL PROGRAM. Davidson JA; Manghi FP; Yu M; Linetzky B; Landó LF Endocr Pract; 2016 Dec; 22(12):1406-1414. PubMed ID: 27540883 [TBL] [Abstract][Full Text] [Related]
11. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Ferdinand KC; Botros FT; Atisso CM; Sager PT Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057 [TBL] [Abstract][Full Text] [Related]
12. Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND. Konig M; Riddle MC; Colhoun HM; Branch KR; Atisso CM; Lakshmanan MC; Mody R; Raha S; Gerstein HC Cardiovasc Diabetol; 2021 Sep; 20(1):194. PubMed ID: 34563178 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial. Tuttolomondo A; Cirrincione A; Casuccio A; Del Cuore A; Daidone M; Di Chiara T; Di Raimondo D; Corte VD; Maida C; Simonetta I; Scaglione S; Pinto A Cardiovasc Diabetol; 2021 Jan; 20(1):1. PubMed ID: 33397395 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Nauck M; Weinstock RS; Umpierrez GE; Guerci B; Skrivanek Z; Milicevic Z Diabetes Care; 2014 Aug; 37(8):2149-58. PubMed ID: 24742660 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized controlled trials. Aroda VR; Frias JP; Ji L; Niemoeller E; Nguyên-Pascal ML; Denkel K; Espinasse M; Guo H; Baek S; Choi J; Lingvay I Diabetes Obes Metab; 2023 Aug; 25(8):2084-2095. PubMed ID: 37013892 [TBL] [Abstract][Full Text] [Related]
17. Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes. Pirro V; Roth KD; Lin Y; Willency JA; Milligan PL; Wilson JM; Ruotolo G; Haupt A; Newgard CB; Duffin KL J Clin Endocrinol Metab; 2022 Jan; 107(2):363-378. PubMed ID: 34608929 [TBL] [Abstract][Full Text] [Related]
18. Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration. Pantalone KM; Patel H; Yu M; Fernández Landó L Diabetes Obes Metab; 2018 Jun; 20(6):1461-1469. PubMed ID: 29430801 [TBL] [Abstract][Full Text] [Related]
19. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Ludvik B; Frías JP; Tinahones FJ; Wainstein J; Jiang H; Robertson KE; García-Pérez LE; Woodward DB; Milicevic Z Lancet Diabetes Endocrinol; 2018 May; 6(5):370-381. PubMed ID: 29483060 [TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes. Berra CC; Resi V; Mirani M; Folini L; Rossi A; Solerte SB; Fiorina P Pharmacol Res; 2020 Sep; 159():104996. PubMed ID: 32574827 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]